tbuckley/cabot-search huggingface dataset:
18F-FDG-PET/CT in the Staging and Management of Melanoma
Authors: Amit Singnurkar, Jonathan Wang, Anthony M. Joshua, Deanna L. Langer, Ur Metser
Journal: Clinical Nuclear Medicine (2015)

The Ontario PET Registry was established to provide evidence on the clinical impact of 18-FDG-PET/CT (PET) imaging to inform Ontario Health Insurance Plan funding decisions. The melanoma registry assessed the use of melanoma staging by PET in advanced or high-risk melanoma as a useful adjunct to clinical and standard radiologic investigation.Between January 2011 and July 2013, approximately 319 consecutive patients with potentially resectable localized high-risk melanoma or recurrent disease under consideration for metastasectomy underwent PET imaging for staging across 9 institutions in Ontario. Pre-PET stage information was provided by the referring clinician and compared with post-PET stage. The ability of PET to reclassify disease from M0 to M1 status was assessed. The registry data were then linked to provincial administrative databases using deidentified health insurance numbers to determine PET stage-based rates of systemic therapy, radiotherapy, and surgery.There was a significant increase in stage to M1 status after PET in 56 of 319 patients (17.6%) (P < 0.0001). There was no significant relationship between upstaging with PET and the proportion of patients receiving radiation therapy (P = 0.066) or systemic therapy (P = 0.072). There was a significant relationship between upstaging with PET and the proportion of patients undergoing surgical resection of metastases distant to the primary melanoma site (P = 0.034).This prospective, multicenter registry of high-risk or advanced melanoma found that PET significantly upstages patients and impacts surgical management.
Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals
Authors: Till Wüstemann, Ulrike Bauder-Wüst, Martin Schäfer, Matthias Eder, Martina Benesova, Karin Leotta, Clemens Kratochwil, Uwe Haberkorn, Klaus Kopka, Walter Mier
Journal: Theranostics (2016)

Despite the progress in diagnosis and treatment, prostate cancer (PCa) is one of the main causes for cancer-associated deaths among men. Recently, prostate-specific membrane antigen (PSMA) binding tracers have revolutionized the molecular imaging of this disease. The translation of these tracers into therapeutic applications is challenging because of high PSMA-associated kidney uptake. While both the tumor uptake and the uptake in the kidneys are PSMA-specific, the kidneys show a more rapid clearance than tumor lesions. Consequently, the potential of endoradiotherapeutic drugs targeting PSMA is highly dependent on a sustained retention in the tumor - ideally achieved by predominant internalization of the respective tracer. Previously, we were able to show that the pharmacokinetics of the tracers containing the Glu-urea-based binding motif can be further enhanced with a specifically designed linker. Here, we evaluate an eventual influence of the chelator moiety on the pharmacokinetics, including the tumor internalization. A series of tracers modified by different chelators were synthesized using solid phase chemistry. The conjugates were radiolabeled to evaluate the influence on the receptor binding affinity, the ligand-induced internalization and the biodistribution behavior. Competitive binding and internalization assays were performed on PSMA positive LNCaP cells and the biodistribution of the most promising compound was evaluated by positron emission tomography (PET) in LNCaP-tumor-bearing mice. Interestingly, conjugation of the different chelators did not cause significant differences: all compounds showed nanomolar binding affinities with only minor differences. PET imaging of the (68)Ga-labeled CHX-A''-DTPA conjugate revealed that the chelator moiety does not impair the specificity of tumor uptake when compared to the gold standard PSMA-617. However, strong differences of the internalization ratios caused by the chelator moiety were observed: differences in internalization between 15% and 65% were observed, with the CHX-A''-DTPA conjugate displaying the highest internalization ratio. A first-in-man PET/CT study proved the high tumor uptake of this (68)Ga-labeled PSMA-targeting compound. These data indicate that hydrophobic entities at the chelator mediate the internalization efficacy. Based on its specific tumor uptake in combination with its very high internalization ratio, the clinical performance of the chelator-conjugated Glu-urea-based PSMA inhibitors will be further elucidated.
Abstract B07: Tumor promoting activity of SLC13A3 in metastatic prostate cells
Authors: Aigul Zhunussova, Zhanar Irgebayeva, Bhaswati Sen, Leah Friedman, Saniya Ossikbayeva, Sultan Tuleukhanov, Ari Brooks, Richard Sensenig, Zulfiya Orynbayeva
Journal: Cancer Research (2016)

Abstract Solute carriers are membrane proteins that play an important role in cancer homeostasis by supplying cancer cells with essential building blocks and signaling molecules. Different types of membrane transporters were shown to be overexpressed in tumors in support of tumor growth and survival. Due to high affinity interaction with anticancer drugs they can also significantly contribute to the rapid chemoresistance. There is a limited number of studies on the role of solute carriers in reprogramming of cancer metabolism and signaling, especially in metastatic prostate cancer. Our study enabled us to establish the identity of the prostate cancer solute carrier that supports uptake of succinate and possibly similar energy rich metabolites from tumor microenvironment to promote an elevated energy metabolism of cancer cells. We demonstrated that prostate metastatic DU145 cells acquire Na+-dependent dycarboxylic acid carrier SLC13A3 but normal prostate PrEC cells do not express this protein. An important finding was that only at acidic pH 6.8 prostate cancer cells are capable of consuming exogenous succinate, while physiological pH 7.4 was not favorable for this process. Importantly, succinate transported by SLC13A3 not only accelerates the oxidative phosphorylation of prostate cancer mitochondria but it is also known to stabilize onco-factor HIF-1α. The HIF-involved signaling pathways have been linked to prostate tumorigenesis and chemoresistance and therefore, targeting these pathways by inhibiting cancer specific SLC13A3 has great potential for clinical benefit. In addition, the mechanism of succinate influx via SLC13A3 transporter in metastatic prostate cancer cells could also yield a novel metabolic onco-marker and has the potential to be used for imaging-based diagnostics to detect non-glycolytic tumors. Citation Format: Aigul Zhunussova, Zhanar Irgebayeva, Bhaswati Sen, Leah Friedman, Saniya Ossikbayeva, Sultan Tuleukhanov, Ari Brooks, Richard Sensenig, Zulfiya Orynbayeva. Tumor promoting activity of SLC13A3 in metastatic prostate cells. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr B07.
Distal Migration of a Self-Expandable Metal Oesophageal Stent, Presenting As Constipation
Authors: G.  L.  Williams, K.  Ragunath, M.  Davies, J.  S.  Harvey, G.  A.  O.  Thomas
Journal: Endoscopy (2003)

Self-expanding metal stents form an important part of the palliative management of malignant dysphagia of the oesophagus [1]. Different stent types can be associated with varying complications; metal stents are particularly linked with tumour ingrowth and distal migration [2]. We report a case of distal stent migration leading to complications elsewhere in the gastrointestinal tract, and the problems encountered in dealing with it.
Bariatric/Metabolic Surgery to Treat Type 2 Diabetes in Patients With a BMI &amp;lt;35 kg/m2
Authors: David E. Cummings, Ricardo V. Cohen
Journal: Diabetes Care (2016)

OBJECTIVE Global usage of bariatric surgery has been dictated for the past quarter century by National Institutes of Health recommendations restricting these operations to individuals with a BMI ≥35 kg/m2. Strong evidence now demonstrates that bariatric procedures markedly improve or cause remission of type 2 diabetes mellitus (T2DM), in part through weight-independent mechanisms, and that baseline BMI does not predict surgical benefits on glycemic or cardiovascular outcomes. This impels consideration of such operations as “metabolic surgery,” which is used expressly to treat T2DM, including among patients with a BMI &amp;lt;35 kg/m2 who constitute the majority of people with diabetes worldwide. Here, we review available evidence to inform that consideration. RESULTS A meta-analysis of the 11 published randomized clinical trials (RCTs) directly comparing bariatric/metabolic surgery versus a variety of medical/lifestyle interventions for T2DM provides level 1A evidence that surgery is superior for T2DM remission, glycemic control, and HbA1c lowering. Importantly, this is equally true for patients whose baseline BMI is below or above 35 kg/m2. Similar conclusions derive from meta-analyses of high-quality nonrandomized prospective comparisons. Meta-analysis of all pertinent published studies indicates that T2DM remission rates following bariatric/metabolic surgery are comparable above and below the 35 kg/m2 BMI threshold. The safety, antidiabetes durability, and benefits on other cardiovascular risk factors from bariatric/metabolic surgery appear roughly comparable among patients with a BMI below or above 35 kg/m2. Further studies are needed to extend long-term findings and measure “hard” macrovascular/microvascular outcomes and mortality in RCTs. CONCLUSIONS Extant data, including level 1A evidence from numerous RCTs, support new guidelines from the 2nd Diabetes Surgery Summit that advocate for the consideration of bariatric/metabolic surgery as one option, along with lifestyle and medical therapy, to treat T2DM among patients with a BMI &amp;lt;35 kg/m2.
Effect of Carcinogens on Small Organisms. IV. Exposure of Bacteria to High Temperatures
Authors: R. R. Spencer, M. B. Melroy
Journal: JNCI Journal of the National Cancer Institute (1942)

Effect of Carcinogens on Small Organisms. IV. Exposure of Bacteria to High Temperatures Get access R. R. Spencer, R. R. Spencer assistant chief Search for other works by this author on: Oxford Academic PubMed Google Scholar M. B. Melroy M. B. Melroy assistant bacteriologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 3, Issue 1, August 1942, Pages 1–5, https://doi.org/10.1093/jnci/3.1.1 Published: 01 August 1942
Outbreak of Salmonella gastroenteritis among attendees of a restaurant opening in Grece, June 1998
Authors: C Hadjichristodoulou, E Nikolakopoulou, K Karabinis, E Karakou, A Markogiannakis, C Panoulis, M Lampiri, P Tassios
Journal: Eurosurveillance (1999)

Until recently the system for reporting infectious diseases in Greece was inadequate, but a new laboratory reporting system was introduced in 1998, in which collaborating laboratories throughout Greece report each week by e-mail or fax using standard form
Case 35-1966
Authors: Raymond D. Adams, Robert E. Scully
Journal: New England Journal of Medicine (1966)

Presentation of CaseA forty-one-year-old foreman in a sheet-metal factory was admitted to the hospital because of unconsciousness.He had been well until several months previously, when night sweats, which had occurred for many years, became more prominent. Two months before entry he complained of weakness and difficulty in performing his work. A physician told him that he had bronchitis and advised him to give up smoking. While having dinner on the day before admission he suddenly grasped his ears, complaining of impairment of hearing and a sensation of distant voices, and stated that his vision was blurry and that . . .
Deuterium-Hydrogen Exchange Coupled With Mass Spectrometry Revealed A Novel Autoantibody Binding Epitope and Substrate Recognition Site In ADAMTS13 Protease,
Authors: Veronica C. Casina, Wenbing Hu, Hayley A. Hanby, Don L. Siegel, Leland Mayne, S. Walter Englander, X. Long Zheng
Journal: Blood (2013)
Marijuana intoxication by passive inhalation: documentation by detection of urinary metabolites
Authors: P Zeidenberg, R Bourdon, G G Nahas
Journal: American Journal of Psychiatry (1977)

During the course of a study on the effects of chronic, heavy marijuana use, a placebo control subject reported dizziness and nausea, showed tachycardia and conjunctivitis, and was found to have urinary cannabinoid metabolites. Staff members observing the marijuana smokers also complained of similar subjective symptoms. The detection of cannabinoids in the urine of this nonsmoker documents the previously anecdotal concept of the "contact high" and has implications for marijuana research and for precautions that may be necessary should marijuana become legal.
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia
Authors: Rachel Thijssen, Johanna ter Burg, Brett Garrick, Gregor G. W. van Bochove, Jennifer R. Brown, Stacey M. Fernandes, María Solé Rodríguez, Jean-Marie Michot, Michael Hallek, Barbara Eichhorst, Hans Christian Reinhardt, Johanna Bendell, Ingrid A. M. Derks, Roel J. W. van Kampen, Kristen Hege, Marie José Kersten, Torsten Trowe, Ellen H. Filvaroff, Eric Eldering, Arnon P. Kater
Journal: Blood (2016)
Abstract PR12: MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs
Authors: Wang Lu, Hao Zeng, Qiang Wang, Zibo Zhao, Thomas G. Boyer, Xiuwu Bian, Wei Xu
Journal: Cancer Research (2016)

Abstract Chemotherapy continues to be an important treatment to reduce the risk of metastatic breast cancer recurrence. However, many tumors relapse due to the development of multidrug resistance, the mechanisms of which remain poorly understood. Therefore, there is a pressing need to elucidate mechanisms of resistance and discover a sensitive biomarker that could predict patient response to chemotherapeutic drugs. We discovered that chemosensitivity can be predicted by methylation of a mediator of RNA polymerase II transcription subunit 12 (MED12) by coactivator associated arginine methyltransferase 1 (CARM1). MED12 is frequently mutated in human cancers, and loss of MED12 has been shown to induce drug resistance through activation of TGF-βR signaling. We showed that MED12 is a novel substrate of CARM1. Not only are the expression levels of CARM1 and MED12 positively correlated but their high expression predicts better prognosis in human breast cancers after chemotherapy. MED12 was primarily methylated at R1862 by CARM1, and mutation of this site in cell lines resulted in resistance to chemotherapy drugs (e.g. 5-FU). A change in chemosensitivity by altering the methylation status of a single protein in breast cancer cells is unprecedented. Mechanistically, we showed that the methylation-dependent drug response mechanism is distinct from activation of TGF-βR signaling. Further, we found that methylated MED12 potently suppresses p21/WAF1 transcription. Cells defective in MED12 methylation have up-regulated p21 protein, which correlates with poor prognosis in breast cancer patients treated with chemotherapy. Collectively this study identifies MED12-methylation as a sensor for predicting response to commonly used chemo-drugs in human cancers. Citation Format: Wang Lu, Hao Zeng, Qiang Wang, Zibo Zhao, Thomas G. Boyer, Xiuwu Bian, Wei Xu. MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs. [abstract]. In: Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer; Sep 24-27, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2016;76(2 Suppl):Abstract nr PR12.
Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy
Authors: Erika Vacchelli, David P. Enot, Federico Pietrocola, Laurence Zitvogel, Guido Kroemer
Journal: Cancer Research (2016)

Abstract Pattern recognition receptors allow the innate immune system to perceive the presence of microbial products and to launch the first steps of the defense response. Some pattern recognition receptors also sense endogenous ligands that are released from uninfected dying cells, thereby activating immune responses against dead-cell antigens. This applies to toll-like receptors 3 and 4 (TLR3, TLR4), which sense double-stranded RNA and high-mobility group protein B1 (HMGB1), respectively, as well as to formyl peptide receptor-1 (FPR1), which interacts with Annexin A1 (ANXA1) from dead cells. Breast cancer patients who bear loss-of-function alleles in TLR3, TLR4, and FPR1 exhibit a reduced metastasis-free and overall survival after treatment with anthracycline-based adjuvant chemotherapy. These genetic defects are epistatic with respect to each other, suggesting that they act on the same pathway, linking chemotherapy to a therapeutically relevant anticancer immune response. Loss-of-function alleles in TLR4 and FPR1 also affect the prognosis of colorectal cancer patients treated with oxaliplatin-based chemotherapy. Altogether, these results support the idea that conventional anticancer treatments rely on stimulation of anticancer immune responses to become fully efficient. Cancer Res; 76(11); 3122–6. ©2016 AACR.
National field trial of the DSM-III-R diagnostic criteria for self- defeating personality disorder
Authors: R L Spitzer, J B Williams, F Kass, M Davies
Journal: American Journal of Psychiatry (1989)

A national field trial of the criteria for self-defeating personality disorder was conducted in 1986. Among psychiatrists with a special interest in personality disorders there was a lack of consensus as to the need for the category in DSM-III-R. Although the diagnosis was more commonly made for female patients, the disorder was by no means rare in male patients. The diagnostic criteria for the disorder had high sensitivity and specificity. However, a series of analyses indicated that the category had limited descriptive validity and considerable overlap with borderline and dependent personality disorders.
Second-Line Therapy for Endometrial Cancer: The Need for Better Options
Authors: Gini F. Fleming
Journal: Journal of Clinical Oncology (2015)

Article Tools ONCOLOGY GRAND ROUNDS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES ERRATUM. September 22, 2016 ARTICLE CITATION DOI: 10.1200/JCO.2015.61.7225 Journal of Clinical Oncology - published online before print July 20, 2015 PMID: 26195695 Second-Line Therapy for Endometrial Cancer: The Need for Better Options Gini F. FlemingxGini F. FlemingSearch for articles by this author Show More University of Chicago, Chicago, IL https://doi.org/10.1200/JCO.2015.61.7225 First Page Full Text PDF Figures and Tables © 2015 by American Society of Clinical Oncology Errata ERRATUM
(17) Kyrle's disease
Authors: R.S. Matthews
Journal: British Journal of Dermatology (1984)

Journal Article (17) Kyrle's disease Get access R.S. Matthews R.S. Matthews Waveney Hospital, Ballymena, Country Antrim Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 111, Issue s26, 1 July 1984, Pages 63–64, https://doi.org/10.1111/j.1365-2133.1984.tb05287.x Published: 01 July 1984
The Diagnosis and Treatment of Diabetes
Authors: T H OLIVER
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rat Colon Carcinomas Associated with Aflatoxin and Marginal Vitamin A 2 3
Authors: Paul M. Newberne, Adrianne E. Rogers
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Rat Colon Carcinomas Associated with Aflatoxin and Marginal Vitamin A Get access Paul M. Newberne, Paul M. Newberne Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 Search for other works by this author on: Oxford Academic PubMed Google Scholar Adrianne E. Rogers Adrianne E. Rogers Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 50, Issue 2, February 1973, Pages 439–448, https://doi.org/10.1093/jnci/50.2.439 Published: 01 February 1973 Article history Received: 10 August 1972 Accepted: 16 October 1972 Published: 01 February 1973
Incidence and Risk Factors For Pneumocystis Jirovecii pneumonia (PCP) Following Haematopoetic Stem Cell Transplant (HSCT)
Authors: Samar Kulkarni, Mike Dennis, Jim Cavet, John Murray, Jo Tomlins, Zena Salih, Martin Scott, Katalina Balassa, Malcolm Guiver, Ken Mutton, Ed Kaczmarsky, David Kay, Tim Sommerville, Kirsty Dodgson, Sven Armin Sommerfeld, Adrian Bloor
Journal: Blood (2013)
Malignant Mesothelioma
Authors: Richard J. Driscoll, Wallace J. Mulligan, Daniel Schultz, Anthony Candelaria
Journal: New England Journal of Medicine (1988)

THE association between malignant mesothelioma and asbestos exposure is well known.1 2 3 Often the exposure is not obvious, and careful clinical and epidemiologic investigations are required to identify it. We recently investigated five cases of this tumor in a Native American pueblo of approximately 2000 persons. A unique juxtaposition of cultural customs with the presence of an industrial plant exposed this population to asbestos.Malignant mesothelioma was diagnosed in three patients at the Public Health Service Hospital in Santa Fe, New Mexico, between April 1984 and September 1985. A search of the state tumor registry revealed that two additional patients had . . .
Virus of Avian Myeloblastosis. XII. Chemical Constitution&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;3&lt;/xref&gt;
Authors: R. A. Bonar, J. W. Beard
Journal: JNCI Journal of the National Cancer Institute (1959)

Analyses were made of the chemical constitution of the virus of avian myeloblastosis. Studies made by microchemical techniques on samples of purified viruses from individual chickens yielded the values of nitrogen, 9.9; phosphorus, 1.27; pentose nucleic acid, 2.17; and lipide, 35 percent, respectively. No evidence was seen of deoxypentose nucleic acid. The content of phosphorus in excess of that bound in the nucleic acid suggests that much of the lipide may be in the form of phospholipide. Within the limits of the methods employed, the results indicated high uniformity in constitution of specimens from different birds, which corroborates evidence of the homogeneity of purified virus preparations previously obtained by analytical ultracentrifugation and electrophoresis. The findings show that in chemical constitution the virus of avian myeloblastosis does not differ in principle from that of filterable agents causing other diseases in man and animals.